Close Menu

NEW YORK – Takeda Pharmaceutical's mobocertinib has shown promising efficacy and safety in a Phase I/II trial in previously treated, advanced non-small cell lung cancer patients harboring EGFR exon 20 insertions. 

At the American Association for Cancer Research's Virtual Annual Meeting this week, Francois Gonzalvez, on behalf of Takeda, presented data showing that 43 percent of 28 mobocertinib-treated NSCLC patients with EGFR exon 20 insertions saw their tumors shrink and on average their tumors stopped progressing for around 7.3 months.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.